RxDoctor Payments Data

Peter Duch, MD

Cardiovascular Disease · Metuchen, NJNPI 1730108150

Payments from drug & device makers

$789in general payments, 2019–2025

Across 80 payments — averaging $9.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$169
  • E.r. Squibb & Sons, L.L.C.$144
  • Johnson & Johnson$98
  • Sanofi-aventis U.S. LLC$83
  • Pfizer$65
  • Amarin Pharma, Inc.$56
  • plus $174 from 6 others

What the payments were for

  • Food & beverage$77598%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$789 in reported general payments places this provider in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$308,739
Medicare patients
747
Services billed
3,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$322,373
XareltoRivaroxaban91$87,672
EntrestoSacubitril/Valsartan43$55,935
MultaqDronedarone Hcl18$40,241
BrilintaTicagrelor43$38,162
Candesartan Cilexetil233$21,025
Olmesartan Medoxomil576$14,678
Praluent PenAlirocumab21$14,425
VascepaIcosapent Ethyl14$13,886
Bisoprolol Fumarate333$11,258
Ezetimibe255$6,543
Telmisartan136$5,678
Diltiazem 24hr Er (Cd)Diltiazem Hcl177$5,427
Flecainide Acetate89$5,365
ClopidogrelClopidogrel Bisulfate413$5,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$322,373324 claims
Johnson & JohnsonXarelto$98$87,67291 claims
NovartisEntresto$169$55,93543 claims
Sanofi-aventis U.S. LLCMultaq$83$40,24118 claims
AstraZenecaBrilinta$52$38,16243 claims
Arbor Pharmaceuticals, Inc.Edarbi$51$3,68214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Metuchen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →